Association of Codon 72 of P53 Gene Polymorphism with Chronic Hepatitis C Virus Infection: A Case Control Study

Journal of Cell and Molecular Research

مقاله 1، دوره 8، شماره 2 - شماره پیاپی 16، اسفند 2016، صفحه 46-51   

نوع مقاله: Research Articles

شناسه دیجیتال (DOI): 10.22067/jcmr.v8i2.56120

نویسندگان

Sina Gerayli¹؛ Alireza Pasdar²؛ Sina Rostami³؛ Samaneh Sepahi⁴؛ Seyed Mousalreza Hoseini⁴؛ Reza Jahanian⁴؛ Aida Gholoobi⁴؛ Zahra Meshkat^{* 4}؛ Mitra Ahadi⁴

¹Western University

²University of Aberd

³University of Bergen

⁴Mashhad University of Medical Sciences

چکیده

Single nucleotide polymorphism in codon 72 of p53 gene (Arg/Pro) changes p53 protein structure and affects its activities. Hepatitis C virus (HCV) is believed to induce hepatocellular carcinoma and P53 polymorphisms have been associated with human cancers. The aim of this study was to evaluate genetic variants of codon 72 of p53 gene polymorphism in HCV patients and its relationship with HCV infection.
The study was conducted on 67 HCV patients, who were referred to medical centers of Mashhad city, Iran, and 73 healthy people from the same region. Genotyping of codon 72 of p53 gene was performed by PCR-RFLP method.
The distributions of different alleles of p53 polymorphisms did not differ significantly between groups. The respective proportions of Proline homozygotes, heterozygotes, and Arginine homozygotes were 37.31%, 35.82%, 26.86% in patients and 39.72%, 27.39%, and 32.87% in the control group respectively. However, we found no significant differenece for the allelic or genotype distribution between cases and controls.
Our results indicated no strong evidence of association of the p53 polymorphism with HCV infection; however, further investigation is needed in different ethnic groups to elucidate the role of this polymorphism in HCV infection.

کلیدواژه‌ها

Polymorphism؛ P53 gene؛ HCV؛ Genetic epidemiology؛ Iran

مراجع

1. Afshari R., Nomani H., Zaniani F. R., Nabavinia M. S., Mirbagheri Z., Meshkat M., Gerayli S., Rostami S. and Meshkat Z. (2014) Genotype distribution of hepatitis C virus in Khorasan Razavi Province, Iran. Turkish Journal of Medical Sciences 44:656-660.

2. Anzola M., Cuevas N., Lopez-Martı́ M., Saiz A., Burgos J. J. and Martı́ M. (2003) Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. Cancer letters 193:199-205.

3. Chen F., Wang W. and El-Deiry W. S. (2010) Current strategies to target p53 in cancer. Biochemical Pharmacology 80:724-730.

4. Dobner T., Horikoshi N., Rubenwolf S. and Shenk T. (1996) Blockage by adenovirus Erorf6 of transcriptional activation by the p53 tumor suppressor. Science 272:1470-1473.

5. El-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W. and Vogelstein B. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.

6. Friborg J., Kong W.-p., Hottiger M. O. and Nabel G. J. (1999) p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 402:889-894.

7. Goh A. M., Coffill C. R. and Lane D. P. (2011) The role of mutant p53 in human cancer. The Journal of Pathology 223:116-126.

8. Hagn F., Klein C., Demmer O., Marchenko N., Vaseva A., Moll U. M. and Kessler H. (2010) BclxL changes conformation upon binding to wild-type but not mutant p53 DNA binding domain. Journal of Biological Chemistry 285:3439-3450.

9. Hollstein M., Sidransky D., Vogelstein B. and Harris C. C. (1991) p53 mutations in human cancers. Science 253:49-54.

10. Ishido S. and Hotta H. (1998) Complex formation of the nonstructural protein 3 of hepatitis C virus with the p53 tumor suppressor. FEBS Letters 438:258-262.

11. Kawajiri K., Nakachi K., Imai K., Watanabe J. and Hayashi S.-I. (1993) Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 14:1085-1089.

12. Ko L. J. and Prives C. (1996) p53: puzzle and paradigm. Genes and Development 10:1054-1072.

13. Kraemer K. H., Lee M. M. and Scotto J. (1987) Xeroderma pigmentosum: cutaneous, ocular, and neurologic abnormalities in 830 published cases. Archives of Dermatology 123:241-250.

14. Leontieva O. V., Gudkov A. V. and Blagosklonny M. V. (2010) Weak p53 permits senescence during cell cycle arrest. Cell Cycle 9:4323-4327.

15. Leveri M., Gritti C., Rossi L., Zavaglia C., Civardi E., Mondelli M. U., De Silvestri A. and Silini E. M. (2004) Codon 72 polymorphism of P53 gene does not affect the risk of cirrhosis and hepatocarcinoma in HCV-infected patients. Cancer letters 208:75-79.

16. Li T., Kon N., Jiang L., Tan M., Ludwig T., Zhao Y., Baer R. and Gu W. (2012) Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 149:1269-1283.

17. Marcel V., Dichtel-Danjoy M.-L., Sagne C., Hafsi H., Ma D., Ortiz-Cuaran S., Olivier M., Hall J., Mollereau B. and Hainaut P. (2011) Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. Cell Death and Differentiation 18:1815-1824.

18. Minaguchi T., Kanamori Y., Matsushima M., Yoshikawa H., Taketani Y. and Nakamura Y. (1998) No evidence of correlation between polymorphism at codon 72 of p53 and risk of cervical cancer in Japanese patients with human papillomavirus 16/18 infection. Cancer Research 58:4585-4586.

19. Molchadsky A., Rivlin N., Brosh R., Rotter V. and Sarig R. (2010) p53 is balancing development, differentiation and de-differentiation to assure cancer prevention. Carcinogenesis 31:1501-1508.

20. Moriya K., Fujie H., Shintani Y., Yotsuyanagi H., Tsutsumi T., Ishibashi K., Matsuura Y., Kimura S., Miyamura T. and Koike K. (1998) The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nature Medicine 4:1065-1067.

21. Muramatsu S., Ishido S., Fujita T., Itoh M. and Hotta H. (1997) Nuclear localization of the NS3 protein of hepatitis C virus and factors affecting the localization. Journal of Virology 71:4954-4961.

22. Okada F., Shiraki T., Maekawa M. and Sato S. (2001) A p53 polymorphism associated with increased risk of hepatitis C virus infection. Cancer Letters 172:137-142.

23. Papadakis E., Dokianakis D. and Spandidos D. (2000) p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Molecular Cell Biology Research Communications 3:389-392.

24. Sakamuro D., Furukawa T. and Takegami T. (1995) Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. Journal of Virology 69:3893-3896.

25. Sepahi S., Pasdar A., Ahadi M., Gerayli S., Rostami S. and Meshkat Z. (2014) Haplotype analysis of interleukin-10 gene promoter polymorphisms in chronic hepatitis C infection: a case control study. Viral Immunology 27:398-403.

26. Shakeri M. T., Nomani H., Mobarhan M. G., Sima H. R., Gerayli S., Shahbazi S., Rostami S. and Meshkat Z. (2013) The prevalence of hepatitis C virus in mashhad, iran: a population-based study. Hepatitis monthly 13.

27. Själander A., Birgander R., Athlin L., Stenling R., Rutegård J., Beckman L. and Beckman G. (1995) P53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis 16:1461-1464.

28. Sjalander A., Birgander R., Hallmans G., Cajander S., Lenner P., Athlin L., Beckman G. and Beckman L. (1996) p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17:1313-1316.

29. Sotiropoulou P. A., Candi A., Mascre G., De Clercq S., Youssef K. K., Lapouge G., Dahl E., Semeraro C., Denecker G. and Marine J.-C. (2010) Bcl-2 and accelerated DNA repair mediates resistance of hair follicle bulge stem cells to DNA-damage-induced cell death. Nature Cell Biology 12:572-582.

30. Srivastava S., Zou Z., Pirollo K., Blattner W. and Chang E. H. (1990) Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348:747.

31. Storey A., Thomas M., Kalita A., Harwood C., Gardiol D., Mantovani F., Breuer J., Leigh I. M., Matlashewski G. and Banks L. (1998) Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer. Nature 393:229-234.

32. Vossughinia H., Goshayeshi L., Bayegi H. R., Sima H., Kazemi A., Erfani S., Abedini S., Goshayeshi L., Ghaffarzadegan K. and Nomani H. (2012) Prevalence of hepatitis C virus genotypes in Mashhad, Northeast Iran. Iranian Journal of Public Health 41:56-61.

33. Wang F., Yoshida I., Takamatsu M., Ishido S., Fujita T., Oka K. and Hotta H. (2000) Complex formation between hepatitis C virus core protein and p21Waf1/Cip1/Sdi1. Biochemical and Biophysical Research Communications 273:479-484.

34. Wang X. W., Forrester K., Yeh H., Feitelson M. A., Gu J.-R. and Harris C. C. (1994) Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proceedings of the National Academy of Sciences 91:2230-2234.

35. Zehbe I., Voglino G., Wilander E., Genta F. and Tommasino M. (1999) Codon 72 polymorphism of p53 and its association with cervical cancer. The Lancet 354:218-219.

36. Zhao T. and Xu Y. (2010) p53 and stem cells: new developments and new concerns. Trends in Cell Biology 20:170-175.

37. Zhu Z.-Z., Cong W.-M., Liu S.-F., Xian Z.-H., Wu W.-Q., Wu M.-C., Gao B., Hou L.-F. and Zhu G.-S. (2005) A p53 polymorphism modifies the risk of hepatocellular carcinoma among non-carriers but not carriers of chronic hepatitis B virus infection. Cancer letters 229:77-83.

38. Ziech D., Franco R., Georgakilas A. G., Georgakila S., Malamou-Mitsi V., Schoneveld O., Pappa A. and Panayiotidis M. I. (2010a) The role of reactive oxygen species and oxidative stress in environmental carcinogenesis and biomarker development. Chemico-Biological Interactions 188:334-339.

39. Ziech D., Franco R., Pappa A., Malamou-Mitsi V., Georgakila S., Georgakilas A. G. and Panayiotidis M. I. (2010b) The role of epigenetics in environmental and occupational carcinogenesis. Chemico-Biological Interactions 188:340-349.

40. Ziech D., Franco R., Pappa A. and Panayiotidis M. I. (2011) Reactive Oxygen Species (ROS)––Induced genetic and epigenetic alterations in human carcinogenesis. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 711:167-173.